The Yujin Oral Solution Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a liquid active pharmaceutical ingredient supplied for incorporation into multiple veterinary dosage forms. The designation identifies a single liquid grade rather than a finished oral solution; it is intended for further pharmaceutical processing under current good manufacturing practice. In the current technical dossier, no additional numeric model code is assigned beyond the full descriptive name. The grade is released against specification classes covering identity, assay, related substances, residual solvents, elemental impurities, endotoxins, bioburden, viscosity, density, clarity, and pH. In downstream use, the liquid form eliminates dry-milling and particle-size control steps that constrain solid API grades, while placing greater emphasis on solvent residue, chemical stability in solution, and low-endotoxin handling for injectable applications. Manufacturing operations using the product are subject to EU 2019/6 and FDA 21 CFR Part 210/211 where the resulting veterinary medicinal product is registered in the relevant jurisdiction.

What Does the Veterinary Oral Solution Grade Release Specification Cover?

Release testing follows pharmacopoeial and dossier-defined methods. The table below lists representative specification classes; lot-specific values are recorded on the certificate of analysis and may differ according to the registered market. Where a pharmacopoeial monograph applies, assay is commonly controlled from 95.0% to 105.0% of label claim for oral liquid presentations, although internal release limits may be narrower. Because the product is a liquid, particle-size distribution and powder flow are not release attributes. Instead, density and viscosity become critical because they determine dispensing accuracy and line transfer behaviour.

On production-scale liquid API receiving lines, viscosity and density are measured at 20 °C before tank transfer. Positive-displacement diaphragm pumps and magnetically coupled gear pumps are commonly used for metering. Lot-to-lot viscosity variation outside the release band has been observed to shift mass-flow calibration by more than the 2% balance tolerance used in solid dosage form dosing. For this reason, the liquid grade is not treated as a fixed-volume commodity; density-corrected weight measurements are specified for batch charging. Where automated addition is used, load-cell-based mass-flow verification provides better traceability than volumetric counters alone.

Storage of the liquid API requires protection from light and freezing. If a frozen or near-frozen condition occurs, phase separation or precipitation may be irreversible, and the product should be rejected unless a thawing and re-qualification procedure has been validated for the specific container type and fill volume. Published data for this specific configuration is limited, so regional stability data and the marketing authorisation dossier remain the controlling documents.

When One Liquid API Replaces Multiple Solid API Grades

Solid veterinary API grades are typically controlled by particle-size distribution, specific surface area, bulk density, flowability, and sometimes electrostatic charge. Those attributes affect blend uniformity, die filling, roller compaction, and dry granulation. Replacing a solid grade with the oral solution grade removes particle-size distribution as a release attribute and reduces dust exposure during charging. The active is already in solution, so content uniformity challenges in powders and granules shift from mechanical distribution of solid particles to uniform liquid dispersion and drying.

This does not make the liquid grade universally interchangeable. Solution-state chemical stability is the limiting factor. Hydrolytic degradation, oxidation, or microbial growth can occur if the API is held in inadequately sealed containers or exposed to excessive headspace oxygen. The specification therefore includes related substances and bioburden controls intended to detect deterioration before release. In addition, residual solvents are more prominent in a liquid grade than in a dried solid API because the vehicle remains in the product. Downstream users must evaluate whether the stated residual solvent profile is acceptable for the target species and withdrawal period.

A further distinction from solid APIs is the absence of dry-milling heat and shear. Thermally labile actives that degrade during micronization may be handled more safely in solution, provided the solvent system does not introduce a comparable degradation pathway. Conversely, actives that are poorly stable in aqueous or hydroalcoholic vehicles are less suited to this grade. The manufacturer’s dossier limits the permissible dilution matrices and should be consulted before blending with propylene glycol, glycerol formal, benzyl alcohol, or polyethylene glycol grades intended for parenteral use.

Premix, Powder, and Tablet Granulation Transfer Points

The liquid API is introduced at different points depending on the target dosage form. The table below summarises the incorporation point, critical processing parameter, and common equipment class for each format.

Tablet and capsule batches made with the oral solution grade typically introduce the liquid at the wet-granulation stage. A binder solution containing the API is sprayed through a two-fluid nozzle into a high-shear granulator; impeller tip speed and spray rate are adjusted to avoid overwetting. Overwetting produces oversized agglomerates that dry with hard shells and moist cores, causing tablet capping and variable dissolution. Underwetting produces weak granules and poor tablet crushing strength. The same liquid feed can be used in continuous twin-screw granulation, where barrel fill ratio and screw configuration determine granule size distribution more strongly than the API viscosity alone.

For powders and granules, the liquid is adsorbed onto a low-moisture carrier such as microcrystalline cellulose, precipitated silica, or a feed-compatible carrier. Adsorption capacity must be verified by rheological and flow measurements; liquid loading beyond the experimentally determined capacity produces a wet mass that blocks rotary tablet press feed frames or forms non-uniform granules. Residual moisture after drying is controlled by loss on drying and may influence chemical stability, capsule shell integrity, and premix microbial growth.

For veterinary premixes, the liquid grade is sprayed onto a feed carrier under low-shear ribbon blending. The main process risk is segregation after discharge because the API resides on the carrier surface rather than inside a granule. Bulk transport and auger transfer can generate fines that differ in active content from the parent blend. Accordingly, blend uniformity testing and subsequent in-process sampling are required to demonstrate that the active remains distributed after transfer and filling into sacks or bins.

Parenteral processing with the same API requires additional controls. The oral solution grade is not supplied as sterile; therefore downstream sterile filtration or terminal sterilisation is required. The maximum endotoxin level is derived from the finished product specification and the highest veterinary dose per kilogram: the formula K/M is applied, where K is the threshold pyrogenic dose and M is the maximum bolus dose in mg/kg. For a finished parenteral system with a Ph. Eur. 2.6.14 LAL limit of 0.5 EU/mL, the API contribution must be assigned so that the sum of API, excipient, and container closure contributions remains below that limit. Published data for this specific configuration is limited, so each manufacturing site must perform a filter compatibility study using the actual liquid grade and its intended dilution ratio.

Filtration scale-up should include a pre-filtration optimisation trial. Diluted solutions may require a 0.45 μm prefilter before the sterilising 0.22 μm membrane if insoluble excipient fractions or visible particulates appear during mixing. Polyethersulfone and polyvinylidene fluoride membranes are commonly screened; membranes with poor chemical compatibility can exhibit premature fouling or extractable shift. The product should not be assumed autoclavable without temperature-stability data. The current dossier does not provide universal terminal sterilisation parameters, so the final dosage form must be validated for the specific container type, fill volume, and autoclave load pattern.